LY2334737

LY2334737 is an nucleoside analog and is an orally active proagent of Gemcitabine. LY2334737 exhibits inhibitory activity against enterovirus A71 (EV-A71) infection. LY2334737 has antiviral and anticancer effects[1][2].

Product Specifications

CAS Number

[892128-60-8]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Enterovirus; Nucleoside Antimetabolite/Analog

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/ly2334737.html

Purity

98.55

Solubility

DMSO : ≥ 100 mg/mL

Smiles

OC[C@@H]1[C@H](C(F)(F)[C@H](N2C(N=C(C=C2)NC(C(CCC)CCC)=O)=O)O1)O

Molecular Formula

C17H25F2N3O5

Molecular Weight

389.39

Precautions

H302, H315, H319, H335

References & Citations

[1]Pratt SE, et al. Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells. Clin Cancer Res. 2013 Mar 1;19 (5) :1159-68.|[2]Francia G, et al. Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis. Mol Cancer Ther. 2012 Mar;11 (3) :680-9.|[3]Jialei Sun, et al. Drug Repurposing of Pyrimidine Analogs as Potent Antiviral Compounds Against Human Enterovirus A71 Infection With Potential Clinical Applications. Sci Rep. 2020 May 18;10 (1) :8159.